retatrutide phase 2 trial obesity triple agonist Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide hits 28% weight loss

In a resignation message shared publicly by the president, Makary defended his record, citing what he described as dozens of major reforms, including sharply shortened drug review timelines, new guidance for psychedelic therapies, a plausible mechanism pathway for rare disease drugs, and changes to estrogen labelling

At the UroFill Clinic, were dedicated to helping patients with every facet of their lives

The GLP-1 Effect: Smaller Portions, Bigger Expectations As GLP-1 medications reshape eating habits, food scientists are rethinking product formulation to deliver more nutrition, functionality, and value in every bite

A new Ozempic rival helps patients lose fat, but keep their muscle the holy grail for a weight-loss drug It's the holy grail for a weight-loss drug: Stay strong, but lose the fat